Therapy response in AML: a tale of two T cells.
作者信息
Penter Livius, Wu Catherine J
机构信息
Charité-Universitätsmedizin Berlin.
Berlin Institute of Health at Charité-Universitätsmedizin Berlin.
出版信息
Blood. 2024 Sep 12;144(11):1134-1136. doi: 10.1182/blood.2024024593.
Abstract
摘要
相似文献
1
Therapy response in AML: a tale of two T cells.急性髓系白血病中的治疗反应：两种T细胞的故事。
Blood. 2024 Sep 12;144(11):1134-1136. doi: 10.1182/blood.2024024593.
2
Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression.抗CD19嵌合抗原受体T细胞疗法治疗复发/难治性伴有异常CD19表达的t(8;21)急性髓系白血病
Front Immunol. 2025 Jul 21;16:1617589. doi: 10.3389/fimmu.2025.1617589. eCollection 2025.
3
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.REGAL研究：galinpepimut-S与最佳可用疗法作为急性髓系白血病第二次缓解期维持治疗的比较。
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
4
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia.不断发展的策略以克服急性髓细胞白血病 CAR-T 细胞治疗中的障碍。
Expert Rev Hematol. 2024 Nov;17(11):797-818. doi: 10.1080/17474086.2024.2420614. Epub 2024 Oct 30.
5
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.分泌抗CD33/抗CD3双靶向抗体的CD70嵌合抗原受体T细胞克服了急性髓系白血病中的抗原异质性。
Blood. 2025 Feb 13;145(7):720-731. doi: 10.1182/blood.2023023210.
6
CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models.具有增强持久性的靶向CD97的嵌合抗原受体T细胞在多种异种移植模型中根除急性髓系白血病。
Cell Rep Med. 2025 Jun 17;6(6):102148. doi: 10.1016/j.xcrm.2025.102148. Epub 2025 May 26.
7
The Problem of Molecular Target Choice for CAR-T Cells in Acute Myeloid Leukemia Therapy.急性髓系白血病治疗中CAR-T细胞分子靶点选择的问题
Int J Mol Sci. 2025 Jun 6;26(12):5428. doi: 10.3390/ijms26125428.
8
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.IL1RAP 特异性 T 细胞衔接器耗竭急性髓系白血病干细胞。
J Hematol Oncol. 2024 Aug 14;17(1):67. doi: 10.1186/s13045-024-01586-x.
9
CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.嵌合抗原受体T细胞疗法治疗急性髓系白血病：进展与结果
Mol Ther. 2025 Jun 4;33(6):2441-2453. doi: 10.1016/j.ymthe.2025.03.052. Epub 2025 Apr 2.
10
The dual effect of interferon-γ in acute myeloid leukemia: A narrative review.干扰素-γ在急性髓系白血病中的双重作用：一篇叙述性综述。
Semin Oncol. 2025 Jun;52(3):152347. doi: 10.1016/j.seminoncol.2025.152347. Epub 2025 May 5.
引用本文的文献
1
Identification and functional analysis of as a biomarker associated with immune-related genes in pediatric acute myeloid leukemia.作为儿童急性髓系白血病中与免疫相关基因相关的生物标志物的鉴定及功能分析。
Transl Cancer Res. 2025 May 30;14(5):2858-2873. doi: 10.21037/tcr-24-1595. Epub 2025 May 23.
2
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.一项针对急性髓系白血病患者和异基因造血细胞移植后活动性疾病患者的WT1特异性TCR基因治疗I/II期试验：向NK样表型倾斜会损害T细胞功能和持久性。
Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0.
3
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.急性髓系白血病使治疗性WT1特异性CD8 T细胞受体T细胞向自然杀伤细胞样表型转变，从而损害其功能和持久性。
medRxiv. 2024 Dec 16:2024.12.13.24318504. doi: 10.1101/2024.12.13.24318504.
4
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells.使用抗体或嵌合抗原受体T细胞（CAR-T细胞）靶向急性髓系白血病中的膜抗原
Cancers (Basel). 2024 Oct 28;16(21):3627. doi: 10.3390/cancers16213627.
本文引用的文献
1
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia.CD8+ T 细胞分化和功能障碍可提示急性髓系白血病的治疗反应。
Blood. 2024 Sep 12;144(11):1168-1182. doi: 10.1182/blood.2023021680.
2
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.急性髓细胞白血病的免疫治疗：当前趋势、挑战与策略。
Acta Haematol. 2024;147(2):198-218. doi: 10.1159/000533990. Epub 2023 Sep 6.
3
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.血液系统恶性肿瘤的免疫治疗：成就、挑战与未来前景。
Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.
4
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.联合地西他滨和伊匹单抗治疗晚期髓系疾病的反应和耐药机制。
Blood. 2023 Apr 13;141(15):1817-1830. doi: 10.1182/blood.2022018246.
5
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.免疫功能障碍特征可预测急性髓系白血病的预后，并定义无反应性的检查点阻断微环境。
J Clin Invest. 2022 Nov 1;132(21):e159579. doi: 10.1172/JCI159579.
6
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.急性髓系白血病药物反应与临床结局的综合分析。
Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21.
7
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.移植后复发髓系恶性肿瘤中 CTLA-4 阻断的分子和细胞特征。
Blood. 2021 Jun 10;137(23):3212-3217. doi: 10.1182/blood.2021010867.
8
Immunogenomic Landscape of Hematological Malignancies.血液系统恶性肿瘤的免疫基因组图谱
Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019.
9
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.免疫图谱可预测急性髓系白血病的化疗耐药性和免疫治疗反应。
Sci Transl Med. 2020 Jun 3;12(546). doi: 10.1126/scitranslmed.aaz0463.
10
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.异基因移植后复发 AML 细胞的免疫逃逸。
N Engl J Med. 2018 Dec 13;379(24):2330-2341. doi: 10.1056/NEJMoa1808777. Epub 2018 Oct 31.
Zotero 插件